European Commission Grants SGX945 Orphan Status for Behçet’s Disease
European Commission granted orphan drug designation to Soligenix’s investigational peptide therapy SGX945 for Behçet’s disease, enabling benefits such as market exclusivity and reduced fees in the EU. SGX945, based on the innate defense regulator dusquetide, joins the company’s pipeline targeting rare inflammatory conditions.
1. Orphan Designation Awarded
The European Commission has formally granted orphan drug status to SGX945, Soligenix’s investigational therapy for Behçet’s disease. This designation recognizes the therapy’s potential in treating a rare vasculitis and opens eligibility for specialized regulatory support and incentives.
2. Therapy Profile
SGX945 is built on dusquetide, a synthetic peptide in the innate defense regulator class designed to modulate inflammatory pathways. Preclinical data suggest dusquetide may reduce mucosal inflammation and tissue damage in rare disease settings.
3. Strategic Implications
Orphan status confers up to 10 years of market exclusivity in the EU, protocol assistance and fee reductions, bolstering Soligenix’s development strategy. The company plans to advance SGX945 into clinical studies to capitalize on regulatory benefits and address urgent patient needs.